Sunesis Pharma

SNSS NASDAQ
0.7798
-0.1202
-13.36%
盘后: 0.7500 -0.0298 -3.82% 16:56 06/17 EDT
开盘
0.7300
昨收
0.9000
最高
0.8700
最低
0.7300
成交量
162.60万
成交均量(3M)
104.45万
52周最高
2.600
52周最低
0.2000
换手率
2.24%
市值
5,655.73万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Sunesis Pharma SNSS股票价格,Sunesis Pharma股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company's other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.
展开 >

最近浏览

名称
价格
涨跌幅